The effect of quercetin drug on inflammatory markers in patients with ulcerative colitis

The effect of quercetin on inflammatory markers in patients with ulcerative colitis: A randomized placebo-controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210531051459N4

Enrollment

Registered

2026-03-16

Start date

2026-05-10

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis. Ulcerative colitis

Interventions

Intervention 1: Intervention group: The enrolled patients take 500 mg herbal quercetin capsule (3,3',4',5,7-pentahydroxyflavone) daily for 3 months. Intervention 2: Control group: The enrolled patient

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Conscious consent to participate in the study patients with mild to moderate ulcerative colitis Aged 18 years and older

Exclusion criteria

Exclusion criteria: Dissatisfaction with participating in the study Pregnancy and lactation Taking of anti-TNF and other biological drugs in the last three months Consumption of quercetin in the last three months Taking of crocin and curcumin supplementations History of liver and kidney failures and cardiovascular diseases Cancer and autoimmune diseases History of bowel resection Sepsis or penomonia

Design outcomes

Primary

Measure	Time frame
Level of inflammatory marker IL-6. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.;Level of stool calprotection. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Stool sampling.;Level of inflammatory marker CRP. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.	—

Measure

Time frame

Level of inflammatory marker IL-6. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.;Level of stool calprotection. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Stool sampling.;Level of inflammatory marker CRP. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.

—

Secondary

Measure	Time frame
Lipid profile levels including LDL, HDL, cholesterol and triglyceride. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.;Levels of liver enzymes ALT and AST. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.;Bilirubin level. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.;Urea level. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.;Creatinine level. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.;Clinical signs based on Simple Clinical Colitis Activity Index (SCCAI). Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Sum of questions in questionnaire.;Score of life quality based on Inflammatory Bowel Disease (IBDQ) questionnaire. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Sum of questions in questionnaire.	—

Measure

Time frame

Lipid profile levels including LDL, HDL, cholesterol and triglyceride. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.;Levels of liver enzymes ALT and AST. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.;Bilirubin level. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.;Urea level. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.;Creatinine level. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Blood sampling and serum isolation.;Clinical signs based on Simple Clinical Colitis Activity Index (SCCAI). Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Sum of questions in questionnaire.;Score of life quality based on Inflammatory Bowel Disease (IBDQ) questionnaire. Timepoint: Beginning of the study and the end of 3 months. Method of measurement: Sum of questions in questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMona Kabiri

Mashhad University of Medical Sciences

Kabirimn@mums.ac.ir31801100 051

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026